Nutra Immunologicals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 2 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.39 M
About Nutra Immunologicals
Nutra Immunologicals Private Limited (NIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 23 November 2022 (Two years and two months 22 days old ). Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.39 M.
Manish Soni and Prakash Patel serve as directors at the Company.
Company Details
-
Location
Bhopal, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290MP2022PTC063513
-
Company No.
063513
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Nov 2022
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Nutra Immunologicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Soni
|
Director | 23-Nov-2022 | Current |
| Prakash Patel | Director | 23-Nov-2022 | Current |
Financial Performance of Nutra Immunologicals.
Enhance accessibility to Nutra Immunologicals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutra Immunologicals?
Unlock access to Nutra Immunologicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.39 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2024 | State Bank Of India | ₹1.39 M | Open |
How Many Employees Work at Nutra Immunologicals?
Nutra Immunologicals has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutra Immunologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutra Immunologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.